Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Maximum/pain free walking time
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	Mean improvement in pain-free walking time (change from baseline) 12 months 74 seconds with atorvastatin 10 mg daily 39 seconds with placebo	P = 0.13		Not significant
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	Mean improvement in pain-free walking time (change from baseline) 12 months 81 seconds with atorvastatin 80 mg daily 39 seconds with placebo	P = 0.025 for atorvastatin 80 mg daily versus placebo	Effect size not calculated	Atorvastatin 80 mg)
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	Mean improvement in maximal walking time (change from baseline) 12 months 90 seconds with atorvastatin 10 mg daily 50 seconds with placebo	P = 0.37		Not significant
RCT 3-armed trial	354 people with peripheral arterial disease and intermittent claudication In review	Mean improvement in maximal walking time (change from baseline) 12 months 90 seconds with atorvastatin 80 mg daily 50 seconds with placebo	P = 0.37		Not significant
Maximum/pain-free walking distance
Systematic review	146 people with moderate intermittent claudication and ankle brachial index <0.9 2 RCTs in this analysis	Maximum walking distance 6 to 12 months with simvastatin with placebo Absolute results not reported	WMD 104.14 metres 95% CI 61.51 m to 146.77 m Results should be interpreted with caution; significant statistical heterogeneity between RCTs (P <0.001; no explanation of heterogeneity suggested)	Effect size not calculated	Simvastatin